-

Endologix Announces that Scott Huennekens Joins Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that R. Scott Huennekens has been appointed to the Endologix Board of Directors.

Endologix announces that R. Scott Huennekens has been appointed to the Endologix Board of Directors.

Share

Mr. Huennekens is a highly regarded medtech CEO, chairperson, entrepreneur and investor, serving an impressive list of companies. Previously, he led Volcano Corp. (VOLC), a leader in minimally invasive therapy guidance in interventional cardiology, from start-up in 2002 to IPO to its sale to Philips in 2015. He was awarded E&Y’s entrepreneur of the year award in 2010 and was recognized by Goldman Sachs in 2016, 2017, & 2018 as one of the 100 most intriguing entrepreneurs at its annual Builders & Innovators conference. Mr. Huennekens graduated magna cum laude with a BS in Business Administration from the University of Southern California and holds his MBA from the Harvard Business School.

“We are delighted to announce Scott Huennekens as the newest member of our board. With Scott’s extensive background in med-tech as both an operator and board adviser, he will be a valuable asset to the company as we go forward," expressed John Liddicoat, MD, President and CEO of Endologix.

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com.

Contacts

Media Contact
Media inquiries: media@endologix.com

Endologix LLC


Release Versions

Contacts

Media Contact
Media inquiries: media@endologix.com

More News From Endologix LLC

Rhevera Medical Marks 2,000 Patients Treated with the DETOUR® System for Complex Peripheral Arterial Disease

SANTA ROSA, Calif.--(BUSINESS WIRE)--Rhevera Medical (formerly Endologix Holdings, LLC) today announced that more than 2,000 patients have now been treated with percutaneous transmural arterial bypass (PTAB) using the DETOUR® System, a minimally invasive therapy for patients with long, complex superficial femoral artery disease. The total includes patients treated in the DETOUR1 and DETOUR2 clinical studies and patients treated since the system’s commercial launch in July 2023.The DETOUR System,...

Endologix Rebrands as Rhevera Medical

SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix Holdings, LLC today announced Rhevera Medical as its new corporate brand. The new identity reflects the company’s broader commitment to partnering with physicians who treat complex vascular disease and supporting patients whose lives, mobility and independence depend on the company’s technologies. For decades, Endologix has worked alongside physicians who care for patients with serious vascular conditions, including abdominal aortic aneurysms and p...

3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease

SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced publication of 36-month results from the DETOUR2 clinical trial evaluating Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR™ System in the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI).The DETOUR2 Trial is a prospective, single-arm, intern...
Back to Newsroom